Testing a new stroke drug: different doses for people who cannot get standard care
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests a new medication (bevifibatide) to see which dose works best for people having an ischemic stroke who cannot get standard treatments like clot-busting drugs or a procedure to remove the clot. It aims to improve recovery by stopping clots from getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a stroke caused by a blood clot (ischemic stroke) but you cannot get standard clot-busting drugs or a procedure to remove the clot, or those treatments did not help enough.
- Your stroke symptoms are at least moderately severe (score of 3 or more on the NIH stroke scale).
- A brain scan (CTA or MRA) shows no large or medium-sized blocked artery — any blockage is either very small or in tiny branches.
- You do not have a known heart condition like atrial fibrillation or a recent heart attack that could send clots to the brain.
- You are not planning to take two blood thinners (like aspirin plus another) within the first week after stroke.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a clot-dissolving medicine (alteplase or tenecteplase) is safe and effective for people who have had a stroke and are taking a blood thinner (DOAC) like apixaban or rivaroxaban. It aims to see if this treatment can still be given within a few hours of the stroke.
This trial tests whether giving IV TNK (tenecteplase) plus standard stroke care can improve outcomes in some people who have a new stroke but cannot get alteplase (another clot-busting drug) and do not have a large blocked artery that can be treated with a procedure. It’s meant for strokes with “mismatch” findings on scans that suggest salvageable brain tissue.
This trial tests a new medicine called SP-8203 added to standard clot-busting treatment for people having a moderate to severe stroke. The goal is to see if it helps improve recovery and is safe.
This trial checks if adding an interleukin-6 receptor inhibitor (a drug that reduces inflammation) to standard emergency clot removal can improve recovery for people with a severe stroke affecting the back part of the brain (posterior circulation). It is for patients who need urgent treatment within 24 hours of symptom onset.
This trial tests if a medication called tirofiban can help people who had a stroke 4.5 to 24 hours ago and received clot-dissolving treatment (IVT). If you have had a stroke and your symptoms did not improve or got worse after IVT, this study might offer a way to prevent further disability.
This trial tests whether giving a clot-dissolving medication directly into the brain's blood vessels during a standard procedure (mechanical thrombectomy) can improve outcomes for people with a stroke caused by a blockage in a medium-sized artery. It may be an option for patients who arrive at the hospital within 24 hours of symptom onset and have enough salvageable brain tissue.
Hear when a new Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.